In the randomized phase III, CAPItello-291 trial, the efficacy and safety of the addition of capivasertib (an oral inhibitor of all AKT isoforms) to fulvestrant was examined in patients with HR-positive/HER2-negative advanced breast cancer who had a relapse or disease progression during or after treatment with an aromatase inhibitor [6]. The gene discussed is AKT1; the disease is breast carcinoma.